507 related articles for article (PubMed ID: 31122893)
41. Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis.
Flaherty KR; Kolb M; Vancheri C; Tang W; Conoscenti CS; Richeldi L
Eur Respir J; 2018 Aug; 52(2):. PubMed ID: 29946007
[TBL] [Abstract][Full Text] [Related]
42. Study design and rationale for the TETON phase 3, randomised, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis.
Nathan SD; Behr J; Cottin V; Lancaster L; Smith P; Deng CQ; Pearce N; Bell H; Peterson L; Flaherty KR
BMJ Open Respir Res; 2022 Jul; 9(1):. PubMed ID: 35787522
[TBL] [Abstract][Full Text] [Related]
43. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study.
Konstan MW; McKone EF; Moss RB; Marigowda G; Tian S; Waltz D; Huang X; Lubarsky B; Rubin J; Millar SJ; Pasta DJ; Mayer-Hamblett N; Goss CH; Morgan W; Sawicki GS
Lancet Respir Med; 2017 Feb; 5(2):107-118. PubMed ID: 28011037
[TBL] [Abstract][Full Text] [Related]
44. Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis.
Ikeda S; Sekine A; Baba T; Katano T; Tabata E; Shintani R; Sadoyama S; Yamakawa H; Oda T; Okuda R; Kitamura H; Iwasawa T; Takemura T; Ogura T
BMC Pulm Med; 2019 Apr; 19(1):78. PubMed ID: 30975118
[TBL] [Abstract][Full Text] [Related]
45. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial.
Ebata S; Yoshizaki A; Oba K; Kashiwabara K; Ueda K; Uemura Y; Watadani T; Fukasawa T; Miura S; Yoshizaki-Ogawa A; Okiyama N; Kodera M; Hasegawa M; Sato S
Lancet Rheumatol; 2022 Aug; 4(8):e546-e555. PubMed ID: 38294008
[TBL] [Abstract][Full Text] [Related]
46. Exploratory phase 2 study of the novel oral multi-kinase inhibitor TAS-115 in patients with idiopathic pulmonary fibrosis.
Nishioka Y; Homma S; Ogura T; Sato S; Arai N; Tomii K; Kamio K; Sakamoto S; Miyazaki Y; Tomioka H; Hisata S; Handa T; Azuma A
Respir Investig; 2023 Jul; 61(4):498-507. PubMed ID: 37263115
[TBL] [Abstract][Full Text] [Related]
47. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
Flaherty KR; Wells AU; Cottin V; Devaraj A; Walsh SLF; Inoue Y; Richeldi L; Kolb M; Tetzlaff K; Stowasser S; Coeck C; Clerisme-Beaty E; Rosenstock B; Quaresma M; Haeufel T; Goeldner RG; Schlenker-Herceg R; Brown KK;
N Engl J Med; 2019 Oct; 381(18):1718-1727. PubMed ID: 31566307
[TBL] [Abstract][Full Text] [Related]
48. Efficacy and Safety of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis.
Yoon HY; Kim DS; Song JW
Respiration; 2019; 97(3):242-251. PubMed ID: 30332670
[TBL] [Abstract][Full Text] [Related]
49. Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel.
Montouris G; Yang H; Williams B; Zhou S; Laurenza A; Fain R
Epilepsy Res; 2015 Aug; 114():131-40. PubMed ID: 26088896
[TBL] [Abstract][Full Text] [Related]
50. GLPG1205 for idiopathic pulmonary fibrosis: a phase 2 randomised placebo-controlled trial.
Strambu IR; Seemayer CA; Fagard LMA; Ford PA; Van der Aa TAK; de Haas-Amatsaleh AA; Modgill V; Santermans E; Sondag EN; Helmer EG; Maher TM; Costabel U; Cottin V
Eur Respir J; 2023 Mar; 61(3):. PubMed ID: 36328358
[TBL] [Abstract][Full Text] [Related]
51. Effects of Qizhukangxian granules on idiopathic pulmonary fibrosis: a randomized, double blind, placebo-controlled and multicenter clinical pilot trial.
Guo S; Song Y; Feng J; Liu S; Li Y; Liu M; Wei L; Zhang X; Xie H; Sun Z
J Tradit Chin Med; 2020 Aug; 40(4):674-682. PubMed ID: 32744035
[TBL] [Abstract][Full Text] [Related]
52. A 2-Year Observational Study in Patients Suffering from Idiopathic Pulmonary Fibrosis and Treated with Pirfenidone: A French Ancillary Study of PASSPORT.
Jouneau S; Gamez AS; Traclet J; Nunes H; Marchand-Adam S; Kessler R; Israël-Biet D; Borie R; Strombom I; Scalori A; Crestani B; Valeyre D; Cottin V
Respiration; 2019; 98(1):19-28. PubMed ID: 30965332
[TBL] [Abstract][Full Text] [Related]
53. Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis.
Flaherty KR; Fell CD; Huggins JT; Nunes H; Sussman R; Valenzuela C; Petzinger U; Stauffer JL; Gilberg F; Bengus M; Wijsenbeek M
Eur Respir J; 2018 Aug; 52(2):. PubMed ID: 29946005
[TBL] [Abstract][Full Text] [Related]
54. A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis.
Parker JM; Glaspole IN; Lancaster LH; Haddad TJ; She D; Roseti SL; Fiening JP; Grant EP; Kell CM; Flaherty KR
Am J Respir Crit Care Med; 2018 Jan; 197(1):94-103. PubMed ID: 28787186
[TBL] [Abstract][Full Text] [Related]
55. Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis.
Palmer SM; Snyder L; Todd JL; Soule B; Christian R; Anstrom K; Luo Y; Gagnon R; Rosen G
Chest; 2018 Nov; 154(5):1061-1069. PubMed ID: 30201408
[TBL] [Abstract][Full Text] [Related]
56. Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis.
Khalil N; Manganas H; Ryerson CJ; Shapera S; Cantin AM; Hernandez P; Turcotte EE; Parker JM; Moran JE; Albert GR; Sawtell R; Hagerimana A; Laurin P; Gagnon L; Cesari F; Kolb M
Eur Respir J; 2019 Mar; 53(3):. PubMed ID: 30578394
[TBL] [Abstract][Full Text] [Related]
57. Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial.
Naccache JM; Jouneau S; Didier M; Borie R; Cachanado M; Bourdin A; Reynaud-Gaubert M; Bonniaud P; Israël-Biet D; Prévot G; Hirschi S; Lebargy F; Marchand-Adam S; Bautin N; Traclet J; Gomez E; Leroy S; Gagnadoux F; Rivière F; Bergot E; Gondouin A; Blanchard E; Parrot A; Blanc FX; Chabrol A; Dominique S; Gibelin A; Tazi A; Berard L; Brillet PY; Debray MP; Rousseau A; Kerjouan M; Freynet O; Dombret MC; Gamez AS; Nieves A; Beltramo G; Pastré J; Le Borgne-Krams A; Dégot T; Launois C; Plantier L; Wémeau-Stervinou L; Cadranel J; Chenivesse C; Valeyre D; Crestani B; Cottin V; Simon T; Nunes H;
Lancet Respir Med; 2022 Jan; 10(1):26-34. PubMed ID: 34506761
[TBL] [Abstract][Full Text] [Related]
58. Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis.
Vancheri C; Sebastiani A; Tomassetti S; Pesci A; Rogliani P; Tavanti L; Luppi F; Harari S; Rottoli P; Ghirardini A; Kirchgaessler KU; Albera C
Respir Med; 2019 Sep; 156():78-84. PubMed ID: 31445389
[TBL] [Abstract][Full Text] [Related]
59. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
Bone HG; Wagman RB; Brandi ML; Brown JP; Chapurlat R; Cummings SR; Czerwiński E; Fahrleitner-Pammer A; Kendler DL; Lippuner K; Reginster JY; Roux C; Malouf J; Bradley MN; Daizadeh NS; Wang A; Dakin P; Pannacciulli N; Dempster DW; Papapoulos S
Lancet Diabetes Endocrinol; 2017 Jul; 5(7):513-523. PubMed ID: 28546097
[TBL] [Abstract][Full Text] [Related]
60. Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes.
Cottin V
Eur Respir Rev; 2012 Jun; 21(124):161-7. PubMed ID: 22654089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]